ShouTi Scores $100M in Series B
SAN FRANCISCO, CA, ShouTi, a clinical-stage biopharmaceutical company, announced the close of a $100M Series B financing led by BVF Partners.
ShouTi, a clinical-stage biopharmaceutical company, announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).
Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners LP, and co-founder and strategic partner Schrodinger.
With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations.
Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about